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There are data suggesting that inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase signalling may reverse resistance
to fluoropyrimidine treatment. To investigate this further, the INFORM study was an open-label, non-comparative phase II study of
gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE, USA) 250mg daily in combination with 5-fluorouracil (5-FU administered as
an intravenous 400mgm
 2 bolus injection followed by 2800mgm
 2 infusion over 46h and folinic acid administered as a 350mg
infusion over 2h) every 2 weeks for up to 12 cycles in 24 patients with metastatic colorectal cancer refractory to previous
fluoropyrimidine treatment. There were no objective responses. The stable disease rate was 37.5% (95% CI: 18.80, 59.41), median
progression-free survival measured 116 days and overall survival was 226 days. Quality of life was unchanged compared to baseline
values, and the commonest toxicities were diarrhoea, rash and fatigue with 7 out of 24 (29%) patients having a grade 3 or 4 toxicity.
Gefitinib does not sensitise patients with fluoropyrimidine refractory metastatic colorectal cancer to 5-FU chemotherapy.
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Large phase III randomised studies in metastatic colorectal cancer
have demonstrated either response rate (Cunningham et al, 2004)
or time to progression (Gibson et al, 2006; Saif and Cohenuram,
2006) advantages using monoclonal antibodies, such as cetuximab,
directed specifically against the epidermal growth factor receptor
(EGFR). Activation of the tyrosine kinase domain of this receptor
catalyses autophosphorylation and subsequent proliferative and
antiapoptotic cellular signal-transduction cascades (Hirata et al,
2002; Vincenzi et al, 2006). High EGFR expression is associated
with resistance to conventional cytotoxic agents. In vitro data
showed that where there is high constitutive EGFR phosphoryla-
tion, gefitinib synergistically sensitises conventional cytotoxic
agent activity (Cho et al, 2006). A recent trial in 55 heavily pre-
treated patients who had received first-line oxaliplatin and second-
line irinotecan-based regimens for metastatic colorectal carcinoma
showed that cetuximab and irinotecan therapy led to clinically
significant activity, suggesting that in some combinations EGFR
inhibition can lead to chemosensitisation (Vincenzi et al, 2006).
Others reported that cetuximab could reverse clinical resistance to
irinotecan in colorectal cancer (Cunningham et al, 2004).
Gefitinib is a small-molecule anilinoquinazoline inhibitor of
EGFR tyrosine kinase signalling (Hirata et al, 2002; Cho et al, 2006)
related chemically to erlotonib (Tarceva
s). In phase II studies,
gefitinib monotherapy had significant antitumour activity in
previously treated patients with advanced non-small-cell lung
cancer (NSCLC). In phase III trials in NSCLC, however, gefitinib in
combination with cytotoxic chemotherapy was not more effica-
cious than cytotoxic chemotherapy alone (Fukuoka et al, 2003;
Johnson and Arteaga, 2003; Kris et al, 2003; Baselga, 2004;
Giaccone et al, 2004; Thatcher et al, 2005). A number of phase I
and II studies in metastatic colorectal carcinoma have investigated
the effects of gefitinib in combination with standard 5-fluorouracil
(5-FU)-based regimens, with response rates (where evaluated)
ranging from 25 to 59% (Kuo et al, 2005; Cho et al, 2006; Hofheinz
et al, 2006; Wolpin et al, 2006), although these trials did not
include chemotherapy-resistant individuals. Gefitinib plus FOL-
FOX (oxaliplatin plus folinic acid and 5-FU) appeared to have
significantly higher activity than reported in response to FOLFOX
alone in similar historical populations (Kuo et al, 2005; Zampino
et al, 2007).
A previous randomised phase II study has demonstrated that
gefitinib has inhibitory effects on downstream regulators of
cellular transformation in patients with previously treated colo-
rectal cancer (Rothenberg et al, 2005). This, together with data
showing that EGFR inhibition can reverse clinical resistance to
chemotherapy (Cunningham et al, 2004), prompted the current
study. In this trial, we investigated the efficacy and safety of a
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scombination of daily dose of gefitinib and modified de Gramont
5-FU and folinic acid in patients with fluoropyrimidine refractory
metastatic colorectal cancer to determine whether gefitinib could
reverse resistance to 5-FU chemotherapy.
PATIENTS AND METHODS
Eligibility criteria
Between March 2003 and September 2004, we enrolled patients
with advanced measurable, histologically proven colorectal cancer
who had received prior 5-FU or capecitabine either in the adjuvant
setting and relapsing within 6 months of treatment or for locally
advanced/metastatic disease and progressing through treatment.
Patients with a World Health Organization (WHO) performance
status 42, intracerebral disease, other serious conditions and a
life expectancy of o3 months were excluded. Adequate bone
marrow function defined as platelets 4100 10
9/l, white blood
cells 43 10
9/l, neutrophils 41.5 10
9/l, serum creatinine
o180mmoll
 1, ALT or AST o2.5 times the upper limit of normal
or less than five times in the presence of liver metastases were
required at trial entry.
All patients gave written informed consent and approval was
obtained from the East London and the City Research Ethics
Committee. The study followed the Declaration of Helsinki
Principles and good clinical practise guidelines.
Trial design
All patients had a 2-week ‘run-in’ period (days 1–14) during which
they received oral gefitinib (Iressa
s, AstraZeneca, Macclesfield,
UK) 250mg once daily, before commencing combination
chemotherapy with 5-FU administered as a 400mgm
 2 bolus
injection over 5min and as a 2800mgm
 2 infusion over 46h and
with folinic acid administered as a 350mg infusion over 2h, as the
modified de Gramont regime every 14 days. In the absence of dose-
limiting toxicity (DLT), further 14-day treatment cycles could be
administered up to a maximum of 12 cycles in total.
Assessments
Response Evaluation Criteria in Solid Tumours (RECIST)
(Michaelis and Ratain, 2006) was used to assess objective tumour
response by computerised tomography scan at baseline and then
after every 8 weeks until progression. Toxicities were assessed by
National Cancer Institute Common Toxicity Criteria (CTC) version
2.0 every 2 weeks. Disease-related symptoms and quality of life
were compared to baseline using the Functional Assessment of
Cancer Therapy – Colorectal (FACT-C) (Ramsey et al, 2000) at
baseline, at the end of the run-in period and every 8 weeks
thereafter. The questionnaire consisted of 37 statements, which
were categorised into physical well-being (PWB), social/family
well-being, emotional well-being, functional well-being and addi-
tional concerns. Each was analysed separately and a total FACT-C
score was also calculated.
Duration of response was defined as the number of days from
the first documented response of CR or PR until the earlier of
either death or disease progression or the last on-study tumour
assessment. Progression-free survival was defined as the number
of days from the date of first dose of study treatment until the date
of objective documented disease progression.
Statistics
A two-stage design incorporating the ad hoc rule of Green and
Dahlberg (1992) was used to determine the number of patients, up
to a maximum of 39 individuals, required to measure tumour
response rates. The sample size was based on an overall power of
90, 5% significance level and a 2% false negative rate for the first
stage. The baseline response rate on 5-FU alone was assumed to be
5%, and a clinically relevant response rate of 20% on 5-FU/
gefitinib was defined. After 18 patients had entered the study and
received the recommended dose, an interim analysis was to be
performed to determine the objective response rate (CRþPR). If
no patients responded, the study was stopped. If one or more
responses were observed, a further 21 patients were to be entered
into the study. The hypothesis that the response rate was less than
or equal to the baseline rate (5%) was rejected if five or more
responses were observed in total. Overall and progression-free
survival were estimated using the Kaplan and Meier (1958)
method.
RESULTS
From three recruiting centres in London, UK, a total of 24
individuals with a mean age of 64.3 years were enrolled, the
majority with a WHO performance status of 0 or 1 (Table 1). All
had received previous chemotherapy, the majority having had
only one previous regimen that involved 5-FU (18 patients) or
capecitabine (two patients). The remaining four individuals had
received two prior 5-FU- and capecitabine-based regimens. All
patients were analysed for safety and efficacy.
There were no objective tumour responses and all 24 patients
discontinued treatment during the study. The main reason for
Table 1 Demographic and baseline patient characteristics
Demographic or baseline characteristic
Intention to treat/
safety (n¼24)




Mean (s.d.) 64.3 (11.8)
Range 39–83




Site of target lesion (n and % of patients) CT scans were
used in all cases, spiral CT for 10 patients
Colorectal 2 (8.3)
Liver 12 (50.0)
Local/regional/staging lymph nodes 1 (4.2)
Distant metastatic lymph nodes 2 (8.3)
Lung 4 (16.7)
Peritoneum 1 (4.2)
Small bowel 1 (4.2)
Stomach 3 (12.5)
Others (e.g., pericardial effusion) 3 (12.5)
Longest diameter (cm) of target lesion
Mean (s.d.) 5.23 (3.56)
Non-target lesions present (n and % of patients) 11 (45.8)
Prior therapy (n and % of patients)
Chemotherapy 24 (100)
Radiotherapy 7 (29.2)
Other cancer therapy 10 (41.7)
WHO performance status (n and % of patients)
Normal activity 11 (45.8)
Restricted activity 12 (50.0)
In bed p50% of the time 1 (4.2)
CT¼computerised tomography; WHO¼World Health Organization.
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sdiscontinuation was objective disease progression in 10 individuals
(42%). Five patients received the maximum 12 cycles. Stable
disease, confirmed and sustained on two consecutive 8-weekly
visits, was achieved in 37.5% (95% CI: 18.80, 59.41; 9 out of 24) of
patients. The Kaplan–Meier survival estimate for percentage of
patients who were progression-free at 6 months was 35% (95% CI:
15.2, 54.8). Progression-free survival time was estimated to be a
median of 116 days (95% CI: 72, 183). Five (20.8%) patients were
alive at 6 months in the intent-to-treat analysis set. The Kaplan–
Meier overall survival estimate for the percentage of patients who
were alive at 6 months was 54.2% (95% CI: 34.2, 74.1). Overall
survival time was estimated to be a median of 226 days.
Nineteen (79%) individuals completed the FACT-C scores
(Table 2). There were no demonstrable changes from baseline
throughout the study, with a median time to worsening of
symptoms of 83 days (interquartile range 56–182 days). The only
significant difference from baseline was the change in PWB from
baseline to visit 7 (a mean deterioration of 4.67, P¼0.03), although
it should be noted that this was based on just seven patients, so
little should be drawn from this result. Overall, the FACT-C scores
in response to the questions about their quality of life and
additional concerns indicated that there had been little or no
change from baseline.
All 24 patients experienced at least one adverse event; the
majority of these were mild (CTC grade 1 or 2), and seven patients
(29%) had a CTC grade 3 or 4 adverse event that was considered to
be drug-related (Table 3). Overall, diarrhoea, nausea, fatigue and
vomiting were the mostly commonly reported toxicities, and 12
patients (50%) discontinued owing to side effects. Dehydration
and malaise were the only drug-related grade 3 or 4 adverse events
reported by more than one patient; dehydration was reported by
two patients (one related to gefitinib, one related to gefitinib/5-FU
chemotherapy combination) and malaise was reported by two
patients.
One patient, a 66-year-old female with a history of heart disease,
died of a myocardial infarction after three cycles of treatment, and
the infarction was presumed causally unrelated, although a post
mortem was not performed.
DISCUSSION
In this study of individuals with fluoropyrimidine refractory
progressive metastatic colorectal carcinoma, the addition of
gefitinib to infusional 5-FU chemotherapy did not significantly
reverse chemoresistance. No responses were observed, in contrast
to other data that suggest that EGFR inhibition may reverse
chemoresistance.
There was some evidence of disease control, with stable disease
rate achieved in 9 (37.5%) patients, and the median progression-
free survival time was 116 days, with a median overall survival of
226 days. The incidence and severity of drug-related adverse events
showed that gefitinib in combination with 5-FU and folinic acid
had an acceptable side effect profile and that synergistic diarrhoea
and other toxicities were not evident.
The lack of responses observed here is compatible with the
previous phase II study reported by Rothenberg et al (2005), in
which 115 patients with metastatic colorectal cancer received
either 250 or 500mg of daily gefitinib and only one partial
response was observed, although a trend towards decreased post-
treatment levels of activated Akt and Ki67 was observed in patients
with a progression-free survival higher than the median. In a
recent study combining gefitinib and irinotecan in patients with
fluoropyrimidine-refractory, irinotecan-naive metastatic disease,
there was no additional benefit from gefitinib (Chau et al, 2007).
However, gefitinib plus FOLFOX appeared to have significantly
higher activity than control populations treated with chemo-
therapy alone (Kuo et al, 2005; Zampino et al, 2007). Thus, it is
conceivable that chemosensitisation reported with EGFR inhibi-
tion may be related to the cytotoxic used alongside gefitinib,
although it is difficult to compare between different study
populations.
The EGFR inhibitor monoclonal antibodies panitumumab and
cetuximab have significant activity in chemorefractory colorectal
cancer (Gibson et al, 2006; Saif and Cohenuram, 2006), and
cetuximab was shown to reverse clinical resistance to irinotecan
(Cunningham et al, 2004). The reasons for the difference between
the results of the current study and those reported in refractory
colorectal cancer with cetuximab are unclear. Although EGFR copy





Best overall response, n (%)
Improved 1 (5.3) 1 (4.2)
No change 2 (10.5) 2 (8.3)
Worsened 0 (0) 0 (0)
Other 16 (84.2) 21 (87.5)
Improvement rate
N (%) of patients 1 (5.3) 1 (4.2)
95% CIs (0.13, 26.03) (0.11, 21.12)
Control rate
N (%) of patients 3 (15.8) 3 (12.5)
95% CIs (3.38, 39.58) (2.66, 32.36)
Worsened rate
N (%) of patients 0 (0) 0 (0)
95% CIs (0.00, 17.65) (0.00, 14.25)
CI¼confidence interval; FACT-C¼Functional Assessment of Cancer Therapy –
Colorectal; FWB¼functional well-being; ITT¼intention to treat; PWB¼physical
well-being; EWB¼emotional well-being; SWB¼social/family well-being. The PWB,
EWB, SWB, FWB and additional concerns subscale scores and the FACT-C overall
score were derived from the FACT-C questionnaire. The change in score from
baseline to each visit during the treatment period was analysed by the Wilcoxon
signed rank test for the ITT analysis set. The responses to each of the 10 additional
concerns questions at each visit were also summarised for the ITT analysis set. The
FACT-C best overall response was calculated, and the improvement rate, control
rate and worsened rate were presented. The primary analysis population for the
improvement rate included the subset of the ITT population with a baseline FACT-C
score of 128 or less defined as the evaluable for FACT-C improvement set.
Table 3 Toxicity to gefitinib and 5-FU
Safety analysis set (n¼24)
Toxicity, n (%) Grade 1 or 2 Grade 3 or 4
Gefitinib
Rash 5 (20.8) 0
Diarrhoea 3 (12.5) 0
Erythema 3 (12.5) 0
5-FU
Diarrhoea 7 (29.2) 0
Stomatitis 4 (16.7) 1 (4.2)
Nausea 4 (16.7) 0
Alopecia 3 (12.5) 0
Erythema 3 (12.5) 0
Gefitinib/5-FU combination
Diarrhoea 4 (16.7) 0
Fatigue 4 (16.7) 0
Nausea 3 (12.5) 1 (4.2)
5-F¼5-fluorouracil.
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snumber and mutations were not studied here or in previous
studies, higher (750mg daily) doses of gefitinib also showed a lack
of clinical activity (Mackenzie et al, 2005). In laboratory studies,
gefitinib is reported to synergise with some but not other cytotoxic
agents, and the addition of gefitinib to 5-FU resulted in synergistic
apoptotic activity (Van Schaeybroeck et al, 2005). Sequence or
schedule dependence is another possible explanation, as the
synergistic effects of gefitinib with cytotoxic drugs (including 5-
FU) used in colorectal cancer may be dependent on the order of
their administration (Magne et al, 2002; Xu et al, 2003; Shimoyama
et al, 2006). Indeed, in vitro antagonistic effects of gefitinib on cell
kill were observed when it was administered before oxaliplatin,
likely because it inhibited the removal of DNA adducts (Xu et al,
2003). Others have reported similar antagonistic effects related to
sequencing (Morelli et al, 2005).
In summary, this study does not show evidence that EGFR
inhibition using the oral tyrosine kinase inhibitor gefitinib
significantly reverses clinical resistance to 5-FU. This contrasts
with laboratory studies and also with clinical studies of EGFR
inhibition using monoclonal antibodies in refractory colorectal
cancer. The reasons for the differences in clinical outcomes
between EGFR tyrosine kinase inhibition by small molecules and
by monoclonal antibodies remain unclear.
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